A Multicenter Study to Evaluate Long-term Safety and Tolerability of Open Label Sacubitril/Valsartan in Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed Study CLCZ696B2319
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Novartis; Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 16 Jul 2024 Primary endpoints has been amended.
- 11 Apr 2024 This trial has been completed in Portugal (End Date: 29 Dec 2023).
- 09 Apr 2024 Status changed from active, no longer recruiting to completed.